Estimating progression-free survival in patients with glioblastoma using routinely collected data

Abstract

Glioblastoma (GBM) represents 80% of all primary malignant brain tumours in adults. Prognosis is poor, and there is a clear correlation between disease progression and deterioration in functional status. In this pilot study we assess whether we can estimate disease progression and progression free survival (PFS) from routinely collected electronic healthcare data. We identified fifty patients with glioblastoma who had chemo-radiotherapy. For each patient we manually collected a reference data set recording demographics, surgery, radiotherapy, chemotherapy, follow-up and death. We also obtained an electronic routine data set for each patient by combining local data on chemotherapy/radiotherapy and hospital admissions. We calculated overall survival (OS) and PFS using the reference data set, and estimated them using the routine data sets using two different methods, and compared the estimated measures with the reference measures. Overall survival was 68% at 1 year and median OS was 12.8 months. The routine data correctly identified progressive disease in 37 of 40 patients and stable disease in 7 of 10 patients. PFS was 7.4 months and the estimated PFS using routine data was 9.1 and 7.8 months with methods 1 and 2 respectively. There was acceptable agreement between reference and routine data in 49 of 50 patients for OS and 35 of 50 patients for PFS. The event of progression, subsequent treatment and OS are well estimated using our approach, but PFS estimation is less accurate. Our approach could refine our understanding of the disease course and allow us to report PFS, OS and treatment nationally.Electronic supplementary materialThe online version of this article (doi:10.1007/s11060-017-2619-1) contains supplementary material, which is available to authorized users.

Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature

“…Therefore, identifying biomarkers which would predict prognosis at an early time point during treatment is crucial. The median PFS is heterogeneous, and frequently ranges from 6 to 8 months [ 27 , 28 ]. In this study, we therefore chose the third quartile (6–9 months after the start of the adjuvant treatment) as a time for measuring microRNAs in serum and serum-derived EVs.…”

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma

“…A separate study used electronic records from 50 patients with GBM to assess OS and PFS in an effort to estimate national OS and PFS using routinely collected data. This study reported that patients treated with chemotherapy and radiotherapy had a median PFS of 7.4 months and median OS at 12.8 months or 68% one-year OS [78]. Therefore, the numbers reported in the GlitIpNi trial are not encouraging.…”

Earliest radiological progression in glioblastoma by multidisciplinary consensus review

“…Glioblastoma progresses in almost all patients. At progression a standard of care is unavailable and management varies from best supportive care or re-challenge of temozolomide to additional combination treatments or clinical trial participation [ 1 – 3 ]. The definition of progressive disease is ambiguous due to unreliable differentiation between treatment-related imaging phenomena and true disease progression.…”